

# Anthony E Lang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7769391/publications.pdf>

Version: 2024-02-01

976  
papers

116,309  
citations

172

154  
h-index

229

306  
g-index

1063  
all docs

1063  
docs citations

1063  
times ranked

52716  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170. | 2.2  | 4,796     |
| 2  | MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.   | 2.2  | 4,389     |
| 3  | Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.  | 6.3  | 4,079     |
| 4  | Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.   | 18.1 | 3,048     |
| 5  | Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1044-1053.  | 13.9 | 1,876     |
| 6  | Phenomenology and classification of dystonia: A consensus update. <i>Movement Disorders</i> , 2013, 28, 863-873.   | 2.2  | 1,754     |
| 7  | Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1651-1661.  | 13.9 | 1,747     |
| 8  | Levodopa and the Progression of Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2498-2508.  | 13.9 | 1,649     |
| 9  | Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2001, 345, 956-963.                              | 13.9 | 1,538     |
| 10 | A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.       | 13.9 | 1,467     |
| 11 | Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013, 80, 496-503.   | 1.5  | 1,445     |
| 12 | Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.   | 2.2  | 1,402     |
| 13 | Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology, The</i> , 2008, 7, 583-590.  | 4.9  | 1,340     |
| 14 | Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.   | 4.9  | 1,244     |
| 15 | Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1130-1143.  | 13.9 | 1,147     |
| 16 | Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999, 163, 94-98.   | 0.3  | 1,143     |
| 17 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.          | 2.2  | 1,097     |
| 18 | Pharmacological Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1670.   | 3.8  | 1,097     |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.  | 2.2  | 1,033     |
| 20 | Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005, 128, 2240-2249.                                | 3.7  | 963       |
| 21 | FRONTAL LOBE DYSFUNCTION IN PARKINSON'S DISEASE. <i>Brain</i> , 1986, 109, 845-883.  | 3.7  | 919       |
| 22 | Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006, 59, 459-466. | 2.8  | 890       |
| 23 | A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.                                 | 13.9 | 830       |
| 24 | Consensus statement on the diagnosis of multiple system atrophy. <i>Clinical Autonomic Research</i> , 1998, 8, 359-362.  | 1.4  | 823       |
| 25 | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.                            | 2.8  | 820       |
| 26 | Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006, 21, S290-S304.                                      | 2.2  | 811       |
| 27 | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. <i>Neurology</i> , 2003, 60, 69-73.  | 1.5  | 771       |
| 28 | THE ANATOMICAL BASIS OF SYMPTOMATIC HEMIDYSTONIA. <i>Brain</i> , 1985, 108, 463-483.   | 3.7  | 666       |
| 29 | Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, 622-628.                         | 2.8  | 653       |
| 30 | Gastrointestinal dysfunction in Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 625-639.   | 4.9  | 653       |
| 31 | Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002, 125, 1196-1209.                                     | 3.7  | 645       |
| 32 | Effect of GPI pallidotomy on motor function in Parkinson's disease. <i>Lancet</i> , The, 1995, 346, 1383-1387.   | 6.3  | 620       |
| 33 | Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. <i>Neurology</i> , 1998, 51, 850-855.                             | 1.5  | 608       |
| 34 | Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.        | 2.2  | 608       |
| 35 | A Controlled Trial of Rasagiline in Early Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1937.  | 4.9  | 559       |
| 36 | PROCEDURAL LEARNING AND NEOSTYRIAL DYSFUNCTION IN MAN. <i>Brain</i> , 1988, 111, 941-960.  | 3.7  | 546       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Tardive dystonia. <i>Neurology</i> , 1982, 32, 1335-1335.   | 1.5  | 534       |
| 38 | Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2006, 96, 3248-3256. | 0.9  | 520       |
| 39 | Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 455.                           | 3.8  | 509       |
| 40 | Corticalâ€basal ganglionic degeneration. <i>Neurology</i> , 1990, 40, 1203-1203.  | 1.5  | 508       |
| 41 | High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997, 42, 292-299.                           | 2.8  | 508       |
| 42 | Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S15-S19.                   | 2.8  | 496       |
| 43 | Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. <i>Brain</i> , 2000, 123, 2091-2108.                        | 3.7  | 488       |
| 44 | Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.                     | 3.7  | 475       |
| 45 | Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.   | 2.2  | 464       |
| 46 | A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008, 131, 2720-2728.   | 3.7  | 460       |
| 47 | Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.   | 4.5  | 455       |
| 48 | Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1036-1043.   | 13.9 | 453       |
| 49 | Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1044-53.   | 4.9  | 446       |
| 50 | Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. <i>Neurology</i> , 2006, 67, 1254-1257.   | 1.5  | 416       |
| 51 | Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1550.  | 4.9  | 397       |
| 52 | Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001, 56, 1702-1706.  | 1.5  | 392       |
| 53 | Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.                         | 2.2  | 382       |
| 54 | Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997, 12, 865-870.   | 2.2  | 379       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.                          | 2.2 | 379       |
| 56 | Definition and classification of hyperkinetic movements in childhood. <i>Movement Disorders</i> , 2010, 25, 1538-1549.  | 2.2 | 374       |
| 57 | Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006, 66, 845-851.   | 1.5 | 371       |
| 58 | Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation. <i>Neurology</i> , 1999, 53, 871-871.  | 1.5 | 362       |
| 59 | Impulse control disorders in parkinson disease: A multicenter caseâ€“control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.   | 2.8 | 361       |
| 60 | Practice parameter: Initiation of treatment for Parkinsonâ€™s disease: An evidence-based review. <i>Neurology</i> , 2002, 58, 11-17.  | 1.5 | 344       |
| 61 | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€“PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.                  | 2.8 | 330       |
| 62 | Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. <i>Annals of Neurology</i> , 1996, 39, 37-45.                            | 2.8 | 329       |
| 63 | Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1460.   | 4.9 | 326       |
| 64 | Factors Associated With Dopaminergic Drugâ€“Related Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 212.                                       | 4.9 | 322       |
| 65 | Prospective prevalence of pathologic gambling and medication association in Parkinson disease. <i>Neurology</i> , 2006, 66, 1750-1752.  | 1.5 | 316       |
| 66 | Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.  | 0.6 | 314       |
| 67 | Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495. | 0.9 | 306       |
| 68 | Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.  | 1.8 | 303       |
| 69 | Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.                      | 4.9 | 303       |
| 70 | Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.                                 | 4.9 | 302       |
| 71 | Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.   | 4.9 | 295       |
| 72 | Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment. <i>Movement Disorders</i> , 1994, 9, 390-394.                | 2.2 | 291       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , 2007, 6, 652-662.  | 4.9  | 290       |
| 74 | Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.  | 3.7  | 286       |
| 75 | Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013, 45, 88-92.  | 9.4  | 281       |
| 76 | Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.   | 4.9  | 279       |
| 77 | Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.  | 0.6  | 278       |
| 78 | Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.   | 2.2  | 275       |
| 79 | Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. <i>Annals of Neurology</i> , 2002, 51, 604-612. | 2.8  | 274       |
| 80 | Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i> , 2006, 3, 192-206.   | 6.0  | 273       |
| 81 | Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.  | 4.5  | 272       |
| 82 | How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. <i>Brain</i> , 2012, 135, 1860-1870.   | 3.7  | 270       |
| 83 | Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002, 97, 1152-1166.  | 0.9  | 267       |
| 84 | A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 297-299.   | 2.2  | 266       |
| 85 | Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. <i>NeuroReport</i> , 1994, 5, 1533-1537.  | 0.6  | 264       |
| 86 | Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.  | 13.9 | 263       |
| 87 | Effects of Apomorphine on Subthalamic Nucleus and Globus Pallidus Internus Neurons in Patients With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2001, 86, 249-260.  | 0.9  | 261       |
| 88 | Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.  | 2.2  | 260       |
| 89 | Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.  | 3.7  | 258       |
| 90 | Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.  | 0.8  | 255       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Î±â€šynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.   | 2.8  | 255       |
| 92  | Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. <i>Neurology</i> , 1999, 53, 561-561.  | 1.5  | 252       |
| 93  | Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.   | 1.5  | 252       |
| 94  | Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.   | 2.8  | 246       |
| 95  | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006, 21, 1941-1946.   | 2.2  | 245       |
| 96  | Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.                                  | 4.9  | 245       |
| 97  | Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.   | 2.2  | 240       |
| 98  | Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.   | 2.8  | 240       |
| 99  | Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.   | 9.4  | 237       |
| 100 | Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. <i>Annals of Neurology</i> , 2003, 54, 271-274.   | 2.8  | 233       |
| 101 | Memory and learning in early Parkinson's disease: Evidence for a â€œfrontal lobe syndromeâ€š. <i>Brain and Cognition</i> , 1990, 13, 211-232.  | 0.8  | 232       |
| 102 | Apraxia in movement disorders. <i>Brain</i> , 2005, 128, 1480-1497.  | 3.7  | 228       |
| 103 | <sc>N</sc>omenclature of genetic movement disorders: <sc>R</sc>ecommendations of the international <sc>P</sc>arkinson and movement disorder society task force. <i>Movement Disorders</i> , 2016, 31, 436-457. | 2.2  | 228       |
| 104 | Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.   | 0.6  | 227       |
| 105 | Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , 2016, 80, 674-685.  | 2.8  | 226       |
| 106 | Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.   | 2.8  | 225       |
| 107 | Levodopaâ€š-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.  | 2.8  | 225       |
| 108 | Randomized Delayed-Start Trial of Levodopa in Parkinsonâ€™s Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.  | 13.9 | 225       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257. | 2.8  | 224       |
| 110 | Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. <i>Neurology</i> , 2007, 68, 457-459.   | 1.5  | 223       |
| 111 | Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.   | 1.1  | 222       |
| 112 | The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.   | 2.2  | 222       |
| 113 | Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.                            | 2.2  | 221       |
| 114 | Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.   | 2.2  | 219       |
| 115 | Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.  | 4.9  | 217       |
| 116 | Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997, 3, 671-674.                                   | 15.2 | 216       |
| 117 | Dementia as the most common presentation of cortical-basal ganglionic degeneration. <i>Neurology</i> , 1999, 53, 1969-1969.   | 1.5  | 214       |
| 118 | Botulinum toxin for simple motor tics. <i>Neurology</i> , 2001, 56, 605-610.  | 1.5  | 208       |
| 119 | Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 290-294.   | 2.8  | 207       |
| 120 | The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.   | 2.4  | 205       |
| 121 | Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003, 61, 1601-1604.   | 1.5  | 204       |
| 122 | Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.                                     | 2.2  | 199       |
| 123 | The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. <i>Human Molecular Genetics</i> , 2004, 13, 3161-3170.                                 | 1.4  | 196       |
| 124 | Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. <i>Experimental Brain Research</i> , 1997, 113, 557-563.                          | 0.7  | 195       |
| 125 | Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.  | 2.8  | 195       |
| 126 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.  | 1.5  | 194       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423. | 4.9 | 192       |
| 128 | Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.  | 2.2 | 191       |
| 129 | Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010, 75, 1711-1716.   | 1.5 | 191       |
| 130 | Effects of apomorphine on globus pallidus neurons in parkinsonian patients. <i>Annals of Neurology</i> , 1997, 42, 767-775.  | 2.8 | 189       |
| 131 | Striatal dopamine distribution in Parkinsonian patients during life. <i>Journal of the Neurological Sciences</i> , 1985, 69, 223-230.  | 0.3 | 188       |
| 132 | Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994, 9, 508-520.   | 2.2 | 188       |
| 133 | <i>L</i> -DJ-1 (PARK7) mutations are less frequent than <i>Parkin</i> (PARK2) mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004, 62, 389-394.  | 1.5 | 188       |
| 134 | Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.   | 2.2 | 188       |
| 135 | Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004, 56, 299-302.  | 2.8 | 186       |
| 136 | Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1125-1132.  | 0.9 | 184       |
| 137 | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.   | 2.2 | 183       |
| 138 | Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 409-415.  | 0.9 | 181       |
| 139 | The "essentials" of essential palatal tremor: a reappraisal of the nosology. <i>Brain</i> , 2006, 129, 832-840.  | 3.7 | 180       |
| 140 | Predicting Motor Decline and Disability in Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1724.   | 4.9 | 179       |
| 141 | Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013, 80, 1698-1701.  | 1.5 | 178       |
| 142 | PAINFUL PARKINSON'S DISEASE. <i>Lancet</i> , The, 1986, 327, 1366-1369.  | 6.3 | 177       |
| 143 | Teaching tape for the motor section of the toronto western spasmodic torticollis scale. <i>Movement Disorders</i> , 1997, 12, 570-575.   | 2.2 | 177       |
| 144 | Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.  | 3.6 | 177       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.   | 4.9 | 174       |
| 146 | Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.   | 4.9 | 172       |
| 147 | Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.   | 2.2 | 171       |
| 148 | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309.  | 1.7 | 170       |
| 149 | Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019, 105, 151-165.  | 2.6 | 170       |
| 150 | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. <i>Brain</i> , 2001, 124, 2105-2118.  | 3.7 | 168       |
| 151 | Toward a redefinition of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 54-60.   | 2.2 | 165       |
| 152 | Multiple system atrophy—parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2012, 27, 1186-1190.  | 2.2 | 164       |
| 153 | Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 136-141.   | 2.2 | 163       |
| 154 | Phenotype in parkinsonian and nonparkinsonian <i>LRRK2</i> G2019S mutation carriers. <i>Neurology</i> , 2011, 77, 325-333.   | 1.5 | 163       |
| 155 | The Fragile X Premutation Presenting as Essential Tremor. <i>Archives of Neurology</i> , 2003, 60, 117.  | 4.9 | 162       |
| 156 | Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1898-904.   | 4.9 | 162       |
| 157 | A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201. | 2.2 | 162       |
| 158 | PARKINSON'S DISEASE AND DEPRESSION. <i>Brain</i> , 1986, 109, 279-292.   | 3.7 | 161       |
| 159 | LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. <i>Neurology</i> , 2005, 65, 696-700.   | 1.5 | 160       |
| 160 | Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. <i>Neurology</i> , 1998, 51, 207-215.  | 1.5 | 157       |
| 161 | Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease. <i>Neurology</i> , 2002, 58, 1665-1672.  | 1.5 | 155       |
| 162 | Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2007, 68, 1782-1789.  | 1.5 | 154       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999, 122, 405-416.  | 3.7 | 153       |
| 164 | The spectrum of levodopa-related fluctuations in Parkinson's disease. <i>Neurology</i> , 1993, 43, 1459-1459.  | 1.5 | 152       |
| 165 | Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. <i>Brain</i> , 1999, 122, 1919-1931.  | 3.7 | 152       |
| 166 | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. <i>Movement Disorders</i> , 2002, 17, S94-S101.  | 2.2 | 150       |
| 167 | Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014, 82, 1791-1797.   | 1.5 | 147       |
| 168 | Frozen shoulder and other shoulder disturbances in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 63-66.  | 0.9 | 145       |
| 169 | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006, 21, 1844-1850.  | 2.2 | 145       |
| 170 | Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.   | 2.2 | 145       |
| 171 | Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. <i>Neurology</i> , 1998, 50, 1015-1020.   | 1.5 | 144       |
| 172 | Gut-brain axis and the spread of $\alpha$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.   | 2.2 | 144       |
| 173 | Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. <i>Human Molecular Genetics</i> , 1995, 4, 1137-1146. | 1.4 | 143       |
| 174 | Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.   | 4.9 | 141       |
| 175 | Myoclonic dystonia. <i>Neurology</i> , 1983, 33, 825-825.  | 1.5 | 141       |
| 176 | A novel locus for inherited myoclonus-dystonia on 18p11. <i>Neurology</i> , 2002, 59, 1183-1186.   | 1.5 | 140       |
| 177 | Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-2766.   | 2.8 | 140       |
| 178 | Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.   | 2.2 | 140       |
| 179 | Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014, 137, 2143-2154.   | 3.7 | 140       |
| 180 | Hypoxic-ischemic damage of the basal ganglia case reports and a review of the literature. <i>Movement Disorders</i> , 1990, 5, 219-224.  | 2.2 | 139       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Survival in Parkinson disease. <i>Neurology</i> , 2005, 64, 87-93.  | 1.5 | 139       |
| 182 | Myoclonus-dystonia: significance of large <i>SGCE</i> deletions. <i>Human Mutation</i> , 2008, 29, 331-332.   | 1.1 | 138       |
| 183 | Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374. | 2.2 | 138       |
| 184 | Psychogenic Dystonia: a Review of 18 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 136-143.   | 0.3 | 137       |
| 185 | Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004, 127, 1252-1268.  | 3.7 | 134       |
| 186 | The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. <i>Human Molecular Genetics</i> , 2001, 10, 1649-1656.   | 1.4 | 133       |
| 187 | Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. <i>Brain</i> , 2001, 124, 1601-1609.  | 3.7 | 133       |
| 188 | Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.  | 2.8 | 133       |
| 189 | Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.   | 2.8 | 132       |
| 190 | Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.  | 4.5 | 132       |
| 191 | Patient perception of tics and other movement disorders. <i>Neurology</i> , 1991, 41, 223-223.  | 1.5 | 132       |
| 192 | Mutations in <i>SLC20A2</i> are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013, 14, 11-22.   | 0.7 | 131       |
| 193 | Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.  | 4.9 | 131       |
| 194 | The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.  | 2.2 | 130       |
| 195 | Colonic mucosal $\alpha$ -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.   | 1.5 | 130       |
| 196 | Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2007, 98, 720-729.                        | 0.9 | 129       |
| 197 | A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.                              | 2.2 | 128       |
| 198 | Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. <i>Annals of Neurology</i> , 2013, 73, 537-545.  | 2.8 | 128       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. <i>Clinical Neurophysiology</i> , 2001, 112, 431-437.   | 0.7 | 127       |
| 200 | Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. <i>Neurology</i> , 2004, 63, 2410-2412.   | 1.5 | 127       |
| 201 | Unusual clinical presentations of cortical-basal ganglionic degeneration. <i>Annals of Neurology</i> , 1996, 40, 893-900.   | 2.8 | 126       |
| 202 | Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.   | 4.9 | 126       |
| 203 | Psychogenic Parkinsonism. <i>Archives of Neurology</i> , 1995, 52, 802-810.   | 4.9 | 125       |
| 204 | Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007, 22, 395-399.  | 2.2 | 125       |
| 205 | Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1179-1181.   | 2.2 | 125       |
| 206 | The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.   | 1.6 | 125       |
| 207 | From psychogenic movement disorder to functional movement disorder: It's time to change the name. <i>Movement Disorders</i> , 2014, 29, 849-852.  | 2.2 | 125       |
| 208 | Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1529-1534.  | 1.1 | 125       |
| 209 | Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [ <sup>11</sup> C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525. | 2.1 | 123       |
| 210 | Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.   | 0.2 | 122       |
| 211 | Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.  | 2.2 | 122       |
| 212 | AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.  | 2.2 | 122       |
| 213 | Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.  | 2.2 | 121       |
| 214 | Botulinum Toxin for Essential Tremor of the Voice With Multiple Anatomical Sites of Tremor: A Crossover Design Study of Unilateral Versus Bilateral Injection. <i>Laryngoscope</i> , 2000, 110, 1366-1374.                        | 1.1 | 120       |
| 215 | Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.   | 4.2 | 120       |
| 216 | Posttraumatic movement disorders: A review. <i>Movement Disorders</i> , 1989, 4, 20-36.   | 2.2 | 119       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012, 79, 659-667.  | 1.5 | 119       |
| 218 | Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.   | 2.1 | 119       |
| 219 | Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. <i>Neuropsychiatry, Neuropsychology and Behavioral Neurology</i> , 2001, 14, 169-76.     | 0.4 | 118       |
| 220 | Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.   | 2.8 | 117       |
| 221 | Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575. | 3.7 | 116       |
| 222 | Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.  | 4.9 | 116       |
| 223 | Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.   | 2.2 | 115       |
| 224 | Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion. <i>Annals of Neurology</i> , 1995, 38, 684-687.                                | 2.8 | 114       |
| 225 | Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.   | 2.2 | 114       |
| 226 | Dystonia in progressive supranuclear palsy.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 352-356.  | 0.9 | 113       |
| 227 | Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003, 60, 917-922.  | 1.5 | 113       |
| 228 | Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.   | 1.5 | 112       |
| 229 | Intracranial Hypotension With Parkinsonism, Ataxia, and Bulbar Weakness. <i>Archives of Neurology</i> , 1999, 56, 869.  | 4.9 | 111       |
| 230 | Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004, 127, 2717-2731.   | 3.7 | 111       |
| 231 | The progression of Parkinson disease. <i>Neurology</i> , 2007, 68, 948-952.   | 1.5 | 109       |
| 232 | Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.                                      | 2.0 | 108       |
| 233 | Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 155-164.  | 2.8 | 107       |
| 234 | Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.  | 2.2 | 107       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 221-225.  | 1.1 | 107       |
| 236 | Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Movement Disorders, 2007, 22, 990-997.  | 2.2 | 106       |
| 237 | Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurology, The, 2008, 7, 927-938.  | 4.9 | 106       |
| 238 | Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. Annals of Neurology, 2009, 66, 110-114.  | 2.8 | 106       |
| 239 | A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.  | 2.2 | 106       |
| 240 | PARKINSON'S DISEASE. Brain, 1987, 110, 35-51.   | 3.7 | 105       |
| 241 | The treatment of dystonic tremor: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 759-769.  | 0.9 | 105       |
| 242 | AAV1/2-induced overexpression of A53T- $\alpha$ -synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathologica Communications, 2017, 5, 11. | 2.4 | 105       |
| 243 | The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.   | 0.9 | 104       |
| 244 | Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. Movement Disorders, 2009, 24, 1001-1008.  | 2.2 | 104       |
| 245 | Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurology, The, 2020, 19, 452-461.   | 4.9 | 104       |
| 246 | Adult-onset subacute sclerosing panencephalitis: Case reports and review of the literature. Movement Disorders, 1997, 12, 342-353.  | 2.2 | 103       |
| 247 | Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. Brain, 2000, 123, 746-758.   | 3.7 | 103       |
| 248 | Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 130-135.   | 0.9 | 103       |
| 249 | Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.  | 1.5 | 103       |
| 250 | Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism and Related Disorders, 2012, 18, S6-S9.  | 1.1 | 102       |
| 251 | Caffeine as symptomatic treatment for Parkinson disease (Caf $\alpha$ -PD). Neurology, 2017, 89, 1795-1803.   | 1.5 | 102       |
| 252 | Subthalamic Nucleus Stimulation: Improvements in Outcome With Reprogramming. Archives of Neurology, 2006, 63, 1266-1272.  | 4.9 | 101       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. <i>Movement Disorders</i> , 2000, 15, 1132-1138.   | 2.2 | 100       |
| 254 | The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.  | 0.9 | 100       |
| 255 | Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.                              | 4.9 | 100       |
| 256 | Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.  | 1.5 | 100       |
| 257 | Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.  | 0.3 | 99        |
| 258 | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Ila clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594. | 2.2 | 99        |
| 259 | Cerebral blood flow changes induced by pedunculo-pontine nucleus stimulation in patients with advanced Parkinson's disease: A [ <sup>15</sup> O] H <sub>2</sub> O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.       | 1.9 | 99        |
| 260 | Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.   | 2.8 | 99        |
| 261 | Psychogenic Movement Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, S94-S100.   | 0.3 | 97        |
| 262 | The cerebello-thalamo-cortical pathway in essential tremor. <i>Neurology</i> , 2003, 60, 1985-1987.  | 1.5 | 97        |
| 263 | Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. <i>Movement Disorders</i> , 2007, 22, 813-821.  | 2.2 | 97        |
| 264 | Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1355-1359.   | 0.9 | 96        |
| 265 | Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 761-765.  | 2.8 | 95        |
| 266 | Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. <i>Archives of Neurology</i> , 2007, 64, 886.  | 4.9 | 95        |
| 267 | Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. <i>Sleep</i> , 2007, 30, 823-827.   | 0.6 | 95        |
| 268 | Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.   | 1.1 | 95        |
| 269 | Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , 1994, 44, 1436-1436.  | 1.5 | 95        |
| 270 | A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.                                 | 1.5 | 94        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | The microbiomeâ€“gutâ€“brain axis in Parkinson disease â€“ from basic research to the clinic. <i>Nature Reviews Neurology</i> , 2022, 18, 476-495.               | 4.9 | 94        |
| 272 | Levodopa-related motor complications-Phenomenology. <i>Movement Disorders</i> , 2008, 23, S509-S514.   | 2.2 | 93        |
| 273 | Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.                             | 2.2 | 93        |
| 274 | Stereotypies: A critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012, 27, 179-185.                              | 2.2 | 93        |
| 275 | Saliency network and parahippocampal dopamine dysfunction in memoryâ€“impaired Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 269-280.                | 2.8 | 93        |
| 276 | How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.            | 2.2 | 93        |
| 277 | Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.   | 2.8 | 92        |
| 278 | Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.              | 2.2 | 92        |
| 279 | Orthostatic tremor arises from an oscillator in the posterior fossa. <i>Movement Disorders</i> , 2001, 16, 272-279.  | 2.2 | 91        |
| 280 | The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S336-S340.  | 1.1 | 91        |
| 281 | Integrated safety of levodopaâ€“carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.                        | 2.2 | 91        |
| 282 | Benign hereditary chorea: Clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003, 54, 244-247.  | 2.8 | 90        |
| 283 | Ataxiaâ€“telangiectasia: A review of movement disorders, clinical features, and genotype correlations. <i>Movement Disorders</i> , 2018, 33, 1238-1247.          | 2.2 | 90        |
| 284 | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.                         | 2.2 | 89        |
| 285 | Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. <i>Brain Pathology</i> , 1998, 8, 355-365.            | 2.1 | 89        |
| 286 | Investigation of C9orf72 in 4 Neurodegenerative Disorders. <i>Archives of Neurology</i> , 2012, 69, 1583.  | 4.9 | 89        |
| 287 | Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. <i>Neuropsychopharmacology</i> , 2015, 40, 546-553. | 2.8 | 89        |
| 288 | Parkinson's diseaseâ€“related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016, 31, 625-631.               | 2.2 | 89        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 289 | Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.  | 1.5  | 89        |
| 290 | Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001, 112, 600-607.   | 0.7  | 88        |
| 291 | Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.   | 2.2  | 88        |
| 292 | Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 1999, 246, 111-115.   | 1.8  | 86        |
| 293 | Mutation analysis of <i>CHCHD10</i> in different neurodegenerative diseases. <i>Brain</i> , 2015, 138, e380-e380.  | 3.7  | 86        |
| 294 | Effects of internal globus pallidus stimulation on motor cortex excitability. <i>Neurology</i> , 2001, 56, 716-723.  | 1.5  | 85        |
| 295 | Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008, 23, 1689-1695.  | 2.2  | 85        |
| 296 | Inhibition of voluntary activity by thalamic stimulation in humans: Relevance for the control of tremor. <i>Movement Disorders</i> , 1997, 12, 727-737.  | 2.2  | 84        |
| 297 | Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. <i>Movement Disorders</i> , 2004, 19, 969-972.   | 2.2  | 84        |
| 298 | Chronic acquired hepatocerebral degeneration: Case reports and new insights. <i>Movement Disorders</i> , 1995, 10, 714-722.  | 2.2  | 83        |
| 299 | Surgery for Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 1118.  | 4.9  | 83        |
| 300 | Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010, 16, 1223-1226.  | 15.2 | 83        |
| 301 | Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011, 134, 2096-2105.   | 3.7  | 83        |
| 302 | Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173. | 3.3  | 83        |
| 303 | Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-66.   | 2.8  | 83        |
| 304 | New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998, 8, 783-790.   | 2.0  | 82        |
| 305 | The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.   | 4.9  | 82        |
| 306 | STIMULUS-SENSITIVE MYOCLONUS IN AKINETIC-RIGID SYNDROMES. <i>Brain</i> , 1992, 115, 1875-1888.   | 3.7  | 81        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 307 | Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003, 18, 1482-1491.  | 2.2  | 81        |
| 308 | Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S113-S117.   | 1.1  | 81        |
| 309 | Olfactory dysfunction in familial parkinsonism. <i>Neurology</i> , 1997, 49, 1262-1267.  | 1.5  | 80        |
| 310 | Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.   | 2.8  | 80        |
| 311 | Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.  | 3.8  | 80        |
| 312 | Homozygous inheritance of the Machado-Joseph disease gene. <i>Annals of Neurology</i> , 1994, 36, 443-447.   | 2.8  | 78        |
| 313 | Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. <i>Movement Disorders</i> , 1999, 14, 585-589.  | 2.2  | 78        |
| 314 | Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.   | 13.9 | 77        |
| 315 | Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.                          | 0.9  | 77        |
| 316 | Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. <i>Neurosurgery</i> , 2003, 53, 1095-1105.   | 0.6  | 76        |
| 317 | Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.  | 0.9  | 76        |
| 318 | Pallidal Deep Brain Stimulation in Cervical Dystonia: Clinical Outcome in Four Cases. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 328-332.  | 0.3  | 75        |
| 319 | â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321. | 0.9  | 75        |
| 320 | Psychogenic dyskinesias in patients with organic movement disorders. <i>Movement Disorders</i> , 1990, 5, 127-133.   | 2.2  | 74        |
| 321 | Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 300-305.  | 0.3  | 74        |
| 322 | Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014, 29, 444-450.  | 2.2  | 74        |
| 323 | Essential pitfalls in â€œessentialâ€ tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.   | 2.2  | 74        |
| 324 | Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.   | 1.5  | 73        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 325 | Peroxisomal D-bifunctional protein deficiency. <i>Neurology</i> , 2014, 82, 963-968.   | 1.5 | 73        |
| 326 | Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.   | 1.5 | 73        |
| 327 | A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.  | 2.2 | 73        |
| 328 | Firing rates of pallidal neurons are similar in Huntingtonâ€™s and Parkinsonâ€™s disease patients. <i>Experimental Brain Research</i> , 2005, 166, 230-236.  | 0.7 | 72        |
| 329 | The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 196-202.   | 0.3 | 72        |
| 330 | Cortical Degeneration in Progressive Supranuclear Palsy. A Comparison with Cortical-Basal Ganglionic Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 726-734.          | 0.9 | 72        |
| 331 | Criteria for deep-brain stimulation in Parkinsonâ€™s disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1695-1705.   | 1.4 | 71        |
| 332 | Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 58-64.                                 | 1.1 | 71        |
| 333 | The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 724-726. | 0.9 | 71        |
| 334 | Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019, 132, 104462.   | 2.1 | 71        |
| 335 | Subthalamic Nucleus Stimulation. <i>Archives of Neurology</i> , 2006, 63, 1266.  | 4.9 | 70        |
| 336 | Fixing the broken system of genetic locus symbols. <i>Neurology</i> , 2012, 78, 1016-1024.   | 1.5 | 70        |
| 337 | Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.   | 3.6 | 70        |
| 338 | Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018, 31, 484-490.   | 1.8 | 69        |
| 339 | Dopa Dose-Dependent Sexual Deviation. <i>British Journal of Psychiatry</i> , 1983, 142, 296-298.   | 1.7 | 68        |
| 340 | A Double-Blind Trial of Clonazepam in Benign Essential Tremor. <i>Clinical Neuropharmacology</i> , 1984, 7, 83-88.   | 0.2 | 68        |
| 341 | Impaired presynaptic inhibition in the motor cortex in Parkinson disease. <i>Neurology</i> , 2009, 72, 842-849.  | 1.5 | 68        |
| 342 | Perampanel, an AMPA antagonist, found to have no benefit in reducing â€œoffâ€•time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.  | 2.2 | 68        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | Subthalamic nucleusâ€”deep brain stimulation for early motor complications in Parkinson's diseaseâ€”the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.                        | 2.2 | 68        |
| 344 | Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.  | 2.2 | 68        |
| 345 | SECONDARY TIC DISORDERS. <i>Neurologic Clinics</i> , 1997, 15, 309-331.  | 0.8 | 67        |
| 346 | Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. <i>Annals of Neurology</i> , 2013, 73, 565-575.  | 2.8 | 67        |
| 347 | Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with Î±-synucleinopathies. <i>Neurobiology of Disease</i> , 2015, 78, 162-171.   | 2.1 | 67        |
| 348 | Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.  | 1.4 | 67        |
| 349 | Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988, 3, 88-94.   | 2.2 | 66        |
| 350 | Phenotypic spectrum and sex effects in eleven myoclonusâ€”dystonia families with Î¼â€”sarcoglycan mutations. <i>Movement Disorders</i> , 2008, 23, 588-592.  | 2.2 | 66        |
| 351 | Bilateral subthalamic stimulation in <i>Parkin</i> and <i>PINK1</i> parkinsonism. <i>Neurology</i> , 2008, 70, 1186-1191.  | 1.5 | 66        |
| 352 | Thalamic deep brain stimulation activates the cerebellothalamocortical pathway. <i>Neurology</i> , 2004, 63, 907-909.  | 1.5 | 65        |
| 353 | Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. <i>Journal of Neuroscience</i> , 2007, 27, 6029-6036.                      | 1.7 | 65        |
| 354 | Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 33-42.   | 0.9 | 65        |
| 355 | Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.  | 1.1 | 65        |
| 356 | Pergolide in late-stage Parkinson disease. <i>Annals of Neurology</i> , 1982, 12, 243-247.   | 2.8 | 64        |
| 357 | Acute onset dystonic camptocormia caused by lenticular lesions. <i>Movement Disorders</i> , 2001, 16, 177-180.   | 2.2 | 64        |
| 358 | Dopamineâ€”agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014, 35, 2499-2506.   | 1.9 | 64        |
| 359 | Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404. | 1.7 | 64        |
| 360 | Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.                  | 1.7 | 64        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 361 | Regional cerebral glucose metabolism in SLE chorea: Further evidence that striatal hypometabolism is not a correlate of chorea. <i>Movement Disorders</i> , 1987, 2, 201-210.                         | 2.2  | 63        |
| 362 | Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.   | 2.2  | 63        |
| 363 | Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.   | 2.2  | 63        |
| 364 | Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.   | 1.1  | 63        |
| 365 | GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.  | 1.5  | 63        |
| 366 | Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.     | 15.2 | 63        |
| 367 | Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, S168-S170.  | 2.2  | 62        |
| 368 | Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. <i>Neurology</i> , 2007, 68, 356-363.   | 1.5  | 62        |
| 369 | Hereditary parkinsonism: Parkinson disease look-alikes? An algorithm for clinicians to <i>PARK</i> genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.                                 | 2.2  | 62        |
| 370 | <i>ATP13A2</i> variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.  | 2.2  | 62        |
| 371 | Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, 311-318. | 0.3  | 61        |
| 372 | Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. <i>Neurology</i> , 2006, 66, 1941-1943.  | 1.5  | 61        |
| 373 | Understanding disability in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 468-472.   | 1.1  | 61        |
| 374 | Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.   | 1.7  | 61        |
| 375 | Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .  | 2.5  | 61        |
| 376 | Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.  | 4.5  | 60        |
| 377 | Involvement of the human subthalamic nucleus in movement preparation. <i>Neurology</i> , 2003, 61, 1538-1545.   | 1.5  | 59        |
| 378 | Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007, 22, 1958-1962.  | 2.2  | 59        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 379 | Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.  | 2.2 | 59        |
| 380 | A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADYâ€PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.  | 1.7 | 59        |
| 381 | [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440.   | 1.7 | 58        |
| 382 | Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.  | 1.5 | 58        |
| 383 | Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999, 14, 674-680.  | 2.2 | 57        |
| 384 | Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.   | 2.2 | 57        |
| 385 | rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. <i>Movement Disorders</i> , 2008, 23, 1051-1054.   | 2.2 | 56        |
| 386 | Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014, 82, 2250-2251.   | 1.5 | 56        |
| 387 | Global investigation and meta-analysis of the C9orf72 (G <sub>4</sub> C <sub>2</sub> ) repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.   | 1.5 | 56        |
| 388 | Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. <i>Journal of Neurophysiology</i> , 2004, 92, 1937-1943.   | 0.9 | 55        |
| 389 | Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. <i>Neurology</i> , 2007, 68, 704-705.   | 1.5 | 54        |
| 390 | Characteristic head drops and axial extension in advanced choreaâ€acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.  | 2.2 | 54        |
| 391 | Launching the movement disorders society genetic mutation database (MDSGene). <i>Movement Disorders</i> , 2016, 31, 607-609.  | 2.2 | 54        |
| 392 | Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721. | 1.2 | 54        |
| 393 | Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 565-570.  | 4.9 | 53        |
| 394 | Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997, 41, 834-835.   | 2.8 | 53        |
| 395 | Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 851-854.   | 2.2 | 53        |
| 396 | Changes in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystonia. <i>Experimental Neurology</i> , 2007, 204, 845-848.                                     | 2.0 | 53        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 397 | Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.   | 1.7 | 53        |
| 398 | Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.   | 3.7 | 53        |
| 399 | Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110. | 1.1 | 53        |
| 400 | When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.  | 1.5 | 52        |
| 401 | Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.  | 1.9 | 52        |
| 402 | Immediate Motor Effects of Stimulation through Electrodes Implanted in the Human Globus Pallidus. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 70, 1-18.   | 0.8 | 51        |
| 403 | Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.   | 0.6 | 51        |
| 404 | MIXED LINEAGE KINASE INHIBITOR CEP-1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE. <i>Neurology</i> , 2008, 71, 462-463.   | 1.5 | 51        |
| 405 | Caffeine consumption and risk of dyskinesia in <sc>CALM</sc>-PD. <i>Movement Disorders</i> , 2013, 28, 380-383.   | 2.2 | 51        |
| 406 | Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.   | 2.8 | 51        |
| 407 | Anticholinergics in Adult-Onset Focal Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982, 9, 313-319.  | 0.3 | 50        |
| 408 | Treatment of progressive supranuclear palsy and corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, S83-S91.   | 2.2 | 50        |
| 409 | Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005, 103, 246-251.   | 0.9 | 50        |
| 410 | Benign hereditary chorea revisited: A journey to understanding. <i>Movement Disorders</i> , 2007, 22, 2297-2305.  | 2.2 | 50        |
| 411 | Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 125-128.  | 0.3 | 49        |
| 412 | Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 198-203.                                | 0.3 | 49        |
| 413 | Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.  | 0.7 | 49        |
| 414 | Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force "An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.                | 2.2 | 49        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | Letters to the editor. <i>Movement Disorders</i> , 1990, 5, 352-355.  | 2.2 | 48        |
| 416 | A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.  | 2.2 | 48        |
| 417 | Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.  | 2.2 | 48        |
| 418 | Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1191-1203.   | 0.9 | 48        |
| 419 | Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.                              | 2.4 | 48        |
| 420 | Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.                   | 1.5 | 48        |
| 421 | Botulinum Toxin Injections in the Treatment of Blepharospasm, Hemifacial Spasm, and Eyelid Fasciculations. <i>Canadian Journal of Neurological Sciences</i> , 1988, 15, 276-280.                  | 0.3 | 47        |
| 422 | Movement sequencing disorders in parkinson's disease. <i>International Journal of Neuroscience</i> , 1993, 73, 183-194.   | 0.8 | 47        |
| 423 | Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998, 9, 325-336.   | 0.8 | 47        |
| 424 | Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 67-75.                                | 0.7 | 47        |
| 425 | Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.  | 2.2 | 47        |
| 426 | Postanoxic symptomatic oscillatory myoclonus. <i>Neurology</i> , 1983, 33, 240-240.   | 1.5 | 47        |
| 427 | Syringomyelic dystonia and athetosis. <i>Movement Disorders</i> , 1999, 14, 684-688.  | 2.2 | 46        |
| 428 | Mutations in the $\mu$ sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. <i>Neurology</i> , 2003, 61, 244-246.  | 1.5 | 46        |
| 429 | Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004, 19, 1209-1214. | 2.2 | 46        |
| 430 | Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.  | 1.8 | 46        |
| 431 | The spectrum of orolingual tremor: A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.   | 2.2 | 46        |
| 432 | Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , The, 2012, 11, 643-650.                         | 4.9 | 46        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 433 | Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.  | 0.9 | 46        |
| 434 | Levodopa challenge test: indications, protocol, and guide. Journal of Neurology, 2021, 268, 3135-3143.  | 1.8 | 46        |
| 435 | Secondary dystonia. Advances in Neurology, 1988, 50, 9-33.  | 0.8 | 46        |
| 436 | Afferents contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1405-1410. | 0.9 | 45        |
| 437 | Posteroventral medial pallidotomy in Parkinson's disease. Journal of Neurology, 1999, 246, 1128-1141.   | 1.8 | 45        |
| 438 | A writing device improves writing in primary writing tremor. Neurology, 2005, 64, 1648-1650.  | 1.5 | 45        |
| 439 | Patient perception of dyskinesia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1112-1115.  | 0.9 | 45        |
| 440 | Acquired neurosyphilis presenting as movement disorders. Movement Disorders, 2012, 27, 690-695.   | 2.2 | 45        |
| 441 | Another face of placebo: The lessebo effect in Parkinson disease. Neurology, 2014, 82, 1402-1409.   | 1.5 | 45        |
| 442 | Minimal change multiple system atrophy: An aggressive variant?. Movement Disorders, 2015, 30, 960-967.  | 2.2 | 45        |
| 443 | Altered gut microbiome and metabolome in patients with multiple system atrophy. Movement Disorders, 2018, 33, 174-176.  | 2.2 | 45        |
| 444 | <i>Helicobacter pylori</i> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. Movement Disorders, 2020, 35, 2250-2260.  | 2.2 | 45        |
| 445 | Alcohol and Parkinson disease. Annals of Neurology, 1982, 12, 254-256.  | 2.8 | 44        |
| 446 | Familial dystonia and visual failure with striatal CT lucencies.. Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 500-509.   | 0.9 | 44        |
| 447 | Motor effects of stimulating the human cerebellar thalamus.. Journal of Physiology, 1995, 489, 287-298.   | 1.3 | 44        |
| 448 | Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. Archives of Neurology, 2003, 60, 1554.  | 4.9 | 44        |
| 449 | Prenatal and Perinatal Morbidity in Children with Tourette Syndrome and Attention-Deficit Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics, 2009, 30, 115-121.          | 0.6 | 44        |
| 450 | Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. Movement Disorders, 2011, 26, 2427-2431.  | 2.2 | 44        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 451 | What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 79-84.            | 0.9 | 44        |
| 452 | Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia".. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 1101-1101. | 0.9 | 43        |
| 453 | Changes in cortical excitability with thalamic deep brain stimulation. <i>Neurology</i> , 2005, 64, 1913-1919.   | 1.5 | 43        |
| 454 | Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1020-1028.                      | 0.9 | 43        |
| 455 | Abolishing the 1â€year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.   | 2.2 | 43        |
| 456 | The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.  | 2.2 | 43        |
| 457 | Presentation of Creutzfeldt-Jakob disease as acute corticobasal degeneration syndrome. <i>Movement Disorders</i> , 2004, 19, 948-949.  | 2.2 | 42        |
| 458 | Electrophysiological features of myoclonusâ€dystonia. <i>Movement Disorders</i> , 2008, 23, 2055-2061.   | 2.2 | 42        |
| 459 | Psychogenic movement disorders: Past developments, current status, and future directions. <i>Movement Disorders</i> , 2011, 26, 1175-1186.   | 2.2 | 42        |
| 460 | Restless Genital Syndrome in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1559.  | 4.5 | 42        |
| 461 | DEMENTIA PREVALENCE IN PARKINSON'S DISEASE. <i>Lancet, The</i> , 1985, 325, 1037.  | 6.3 | 41        |
| 462 | Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000, 47, 369-373.  | 2.8 | 41        |
| 463 | Editorial. <i>Movement Disorders</i> , 2002, 17, 1-2.  | 2.2 | 41        |
| 464 | The proteasomal inhibition model of Parkinson's disease: â€œBoon or bustâ€?. <i>Annals of Neurology</i> , 2006, 60, 158-161.   | 2.8 | 41        |
| 465 | The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 329-336.                             | 0.9 | 41        |
| 466 | Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007, 22, 888-892.  | 2.2 | 41        |
| 467 | Imaging changes associated with cognitive abnormalities in Parkinsonâ€™s disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.  | 1.2 | 41        |
| 468 | Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. <i>Brain</i> , 2017, 140, 1371-1383.  | 3.7 | 41        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 469 | Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020, 27, 975-984.                                    | 1.7 | 41        |
| 470 | Treatment of Parkinson's disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984, 11, 210-220.  | 0.3 | 40        |
| 471 | Can the Lombard effect be used to improve low voice intensity in Parkinson's disease?. <i>International Journal of Language and Communication Disorders</i> , 1992, 27, 121-127.   | 0.7 | 40        |
| 472 | Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 701-702.  | 2.2 | 40        |
| 473 | Inherited myoclonus-dystonia: Evidence supporting genetic heterogeneity. <i>Movement Disorders</i> , 2001, 16, 106-110.  | 2.2 | 40        |
| 474 | Corticobasal degeneration: Selected developments. <i>Movement Disorders</i> , 2003, 18, 51-56.   | 2.2 | 40        |
| 475 | The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1793-1802.   | 2.2 | 40        |
| 476 | Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 364-368.                                      | 0.9 | 40        |
| 477 | Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2016, 7, 780.   | 1.1 | 40        |
| 478 | Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. <i>The Journal of Otolaryngology</i> , 1993, 22, 171-5.  | 0.6 | 40        |
| 479 | Reflex myoclonus in cortical-basal ganglionic degeneration involves a transcortical pathway. <i>Movement Disorders</i> , 1997, 12, 360-369.  | 2.2 | 39        |
| 480 | Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002, 17, i-i.  | 2.2 | 39        |
| 481 | Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013, 28, 1980-1986.                              | 2.2 | 39        |
| 482 | Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015, 85, 425-432.  | 1.5 | 39        |
| 483 | Deep Brain Stimulation in Rare Inherited Dystonias. <i>Brain Stimulation</i> , 2016, 9, 905-910.   | 0.7 | 39        |
| 484 | Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigation. <i>Annals of Neurology</i> , 2017, 82, 543-553.   | 2.8 | 39        |
| 485 | Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999, 90, 468-477. | 0.9 | 38        |
| 486 | Pardoprinox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.   | 2.2 | 38        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 487 | Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 53-57.                                 | 1.1 | 38        |
| 488 | Parkinsonism in alcohol withdrawal: A follow-up study. <i>Movement Disorders</i> , 1990, 5, 36-39.  | 2.2 | 37        |
| 489 | Effects of acute stimulation through contacts placed on the motor cortex for chronic stimulation. <i>Clinical Neurophysiology</i> , 2002, 113, 635-641.                               | 0.7 | 37        |
| 490 | Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 2004, 9, 188-192.  | 2.2 | 37        |
| 491 | Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.                       | 2.2 | 37        |
| 492 | What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.  | 2.2 | 37        |
| 493 | Validation of the Movement Disorder Society Criteria for the Diagnosis of "Repeat Tauopathies". <i>Movement Disorders</i> , 2020, 35, 171-176.  | 2.2 | 37        |
| 494 | Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004, 19, 331-332.   | 2.2 | 36        |
| 495 | Dystonia as a presenting sign of spinocerebellar ataxia type 1. <i>Movement Disorders</i> , 2004, 19, 586-587.  | 2.2 | 36        |
| 496 | Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.  | 0.7 | 36        |
| 497 | Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 647-650.  | 1.1 | 36        |
| 498 | Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.   | 1.5 | 36        |
| 499 | Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016, 37, 1375-1392.  | 1.9 | 36        |
| 500 | [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.   | 1.2 | 36        |
| 501 | Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776. | 2.2 | 36        |
| 502 | High Dose Anticholinergic Therapy in Adult Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 42-46.  | 0.3 | 35        |
| 503 | "Signing tics"? Insights into the pathophysiology of symptoms in Tourette's syndrome. <i>Annals of Neurology</i> , 1993, 33, 212-215.   | 2.8 | 35        |
| 504 | GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.   | 4.9 | 35        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 505 | Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.   | 1.1 | 35        |
| 506 | Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.   | 1.5 | 35        |
| 507 | Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 823-825.  | 0.9 | 33        |
| 508 | Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007, 22, 2113-2116.  | 2.2 | 33        |
| 509 | Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. <i>Basal Ganglia</i> , 2011, 1, 91-95.  | 0.3 | 33        |
| 510 | Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.   | 1.1 | 33        |
| 511 | Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.   | 1.0 | 33        |
| 512 | A Rostrocaudal Gradient for Aromatic Acid Decarboxylase in the Human Striatum. <i>Canadian Journal of Neurological Sciences</i> , 1987, 14, 444-447.  | 0.3 | 32        |
| 513 | Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.  | 0.7 | 32        |
| 514 | Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.   | 2.2 | 32        |
| 515 | Pramipexole as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 370-376. | 1.1 | 32        |
| 516 | Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.   | 0.3 | 32        |
| 517 | Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.   | 2.6 | 32        |
| 518 | Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 527-529.   | 2.2 | 31        |
| 519 | Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 801-804.   | 0.9 | 31        |
| 520 | Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.   | 1.0 | 31        |
| 521 | Homozygous and heterozygous PINK1 mutations: Considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 875-879.  | 2.2 | 31        |
| 522 | Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.   | 2.2 | 31        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 523 | ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.   | 0.8 | 31        |
| 524 | Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1982, 5, 375-388.  | 0.2 | 30        |
| 525 | Progressive Dystonia With Bilateral Putaminal Hypodensities. <i>Archives of Neurology</i> , 1987, 44, 1184-1187.  | 4.9 | 30        |
| 526 | Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995, 10, 489-495.   | 2.2 | 30        |
| 527 | Coexistence of tics and parkinsonism: Evidence for non-dopaminergic mechanisms in tic pathogenesis. <i>Neurology</i> , 1997, 49, 1699-1701.   | 1.5 | 30        |
| 528 | The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.   | 0.8 | 30        |
| 529 | Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.   | 0.2 | 30        |
| 530 | Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.  | 0.6 | 30        |
| 531 | Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017, 38, 283-292.   | 1.9 | 30        |
| 532 | Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.  | 2.8 | 30        |
| 533 | Surgery for levodopa-induced dyskinesias. <i>Annals of Neurology</i> , 2000, 47, S193-9; discussion S199-202.   | 2.8 | 30        |
| 534 | Pain in Gilles de la Tourette Syndrome and Related Tic Disorders. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 439-441.   | 0.3 | 29        |
| 535 | Pallidal and Thalamic Surgery for Parkinson's Disease. <i>Experimental Neurology</i> , 1997, 144, 35-40.  | 2.0 | 29        |
| 536 | Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.  | 2.2 | 29        |
| 537 | Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.   | 2.2 | 29        |
| 538 | Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259. | 1.4 | 29        |
| 539 | The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.   | 2.2 | 28        |
| 540 | Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. <i>Neurology</i> , 1996, 46, 1156-1157.  | 1.5 | 27        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 541 | Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 153-163.   | 0.8 | 27        |
| 542 | Essential palatal tremor: Evidence of heterogeneity based on clinical features and response to sumatriptan. <i>Movement Disorders</i> , 1999, 14, 179-180.  | 2.2 | 27        |
| 543 | Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.  | 2.2 | 27        |
| 544 | Large deletions account for an increasing number of mutations in <i>SGCE</i> . <i>Movement Disorders</i> , 2008, 23, 456-460.   | 2.2 | 27        |
| 545 | Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson's Disease. <i>European Neurology</i> , 2009, 62, 40-48. | 0.6 | 27        |
| 546 | Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. <i>Movement Disorders</i> , 2012, 27, 326-327.   | 2.2 | 27        |
| 547 | The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.   | 0.3 | 27        |
| 548 | Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.  | 0.8 | 27        |
| 549 | Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. <i>The Journal of Otolaryngology</i> , 1995, 24, 345-51.  | 0.6 | 27        |
| 550 | Cardiac Valvulopathy Associated with Pergolide Use. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 27-33.   | 0.3 | 26        |
| 551 | Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 319-323.  | 2.2 | 26        |
| 552 | 'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014, 137, 2628-2630.  | 3.7 | 26        |
| 553 | Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.   | 2.0 | 26        |
| 554 | Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.  | 2.8 | 26        |
| 555 | Dopamine Agonists in the Treatment of Dystonia. <i>Clinical Neuropharmacology</i> , 1985, 8, 38-57.   | 0.2 | 25        |
| 556 | Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 392-395.  | 0.9 | 25        |
| 557 | Isolated diaphragmatic tremor. <i>Neurology</i> , 2007, 69, 689-692.  | 1.5 | 25        |
| 558 | Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.                            | 2.2 | 25        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | Tongue control for swallowing in Parkinson's disease: Effects of age, rate, and stimulus consistency. <i>Movement Disorders</i> , 2011, 26, 1725-1729.   | 2.2 | 25        |
| 560 | Neuropathological findings in chorea-acanthocytosis: new insights into mechanisms underlying parkinsonism and seizures. <i>Acta Neuropathologica</i> , 2014, 127, 613-615.                                   | 3.9 | 25        |
| 561 | Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.  | 1.1 | 25        |
| 562 | Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.   | 4.9 | 25        |
| 563 | Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015, 85, 1283-1292.  | 1.5 | 25        |
| 564 | Neurologic diagnostic criteria for functional neurologic disorders. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2016, 139, 193-212.   | 1.0 | 25        |
| 565 | Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.  | 2.2 | 25        |
| 566 | Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.                             | 0.7 | 25        |
| 567 | ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 635-639.  | 0.8 | 25        |
| 568 | Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.  | 1.4 | 25        |
| 569 | Diagnostic importance of immunological markers in lymphoma involving the central nervous system. <i>Annals of Neurology</i> , 1984, 16, 668-672.   | 2.8 | 24        |
| 570 | Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. <i>Movement Disorders</i> , 1990, 5, 341-351. | 2.2 | 24        |
| 571 | Clinical Findings in a Large Family With a Parkin Ex3 <sup>Δ</sup> 40 Mutation. <i>Archives of Neurology</i> , 2004, 61, 701.  | 4.9 | 24        |
| 572 | Impact of standard of care for psychosis in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1413-1415.   | 0.9 | 24        |
| 573 | Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 304-312.   | 0.9 | 24        |
| 574 | Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010, 67, 412-414.   | 2.8 | 24        |
| 575 | Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.                                    | 0.9 | 24        |
| 576 | Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017, 181, 306-308.e1.                   | 0.9 | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 577 | Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.  | 0.9 | 24        |
| 578 | Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.  | 0.9 | 24        |
| 579 | Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.   | 2.2 | 24        |
| 580 | Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.                      | 1.1 | 24        |
| 581 | What is it?. Case 1, 1995: Psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995, 10, 257-262.  | 2.2 | 23        |
| 582 | Timed tests in parkinson's disease evaluation1. <i>Movement Disorders</i> , 1997, 12, 127-128.   | 2.2 | 23        |
| 583 | Pallidotomy for Tremor. <i>Movement Disorders</i> , 1998, 13, 107-110.   | 2.2 | 23        |
| 584 | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1801-1808.  | 2.2 | 23        |
| 585 | Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 2108.e1-2108.e5.  | 1.5 | 23        |
| 586 | Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.             | 1.1 | 23        |
| 587 | MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 443-444. | 0.9 | 23        |
| 588 | Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 218-220.   | 0.8 | 23        |
| 589 | Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.  | 2.2 | 22        |
| 590 | Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.  | 2.2 | 22        |
| 591 | Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: An open label case series. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 407-412.        | 1.1 | 22        |
| 592 | Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 589-592.   | 2.2 | 22        |
| 593 | Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.                                       | 0.8 | 22        |
| 594 | Idiopathic Parkinson's disease: Revised Concepts of Cognitive and Affective Status. <i>Canadian Journal of Neurological Sciences</i> , 1988, 15, 106-113.  | 0.3 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 595 | Voluntary control and a wider clinical spectrum of essential palatal tremor. <i>Movement Disorders</i> , 2004, 19, 717-719.   | 2.2 | 21        |
| 596 | Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1194-1195.                | 0.9 | 21        |
| 597 | Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 601-604.                          | 1.3 | 21        |
| 598 | A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016, 17, 245-249.   | 0.7 | 21        |
| 599 | Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.                                      | 1.1 | 21        |
| 600 | Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.             | 0.9 | 21        |
| 601 | Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282. | 1.5 | 21        |
| 602 | Subcognitive Processing in the Frontocaudate "Complex Loop". <i>Alzheimer Disease and Associated Disorders</i> , 1990, 4, 150-160.                                    | 0.6 | 20        |
| 603 | Measuring motor complications in clinical trials for early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 143-146.         | 0.9 | 20        |
| 604 | Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , The, 2006, 5, 990-991.                                 | 4.9 | 20        |
| 605 | Childhood Onset in Familial Prion Disease With a Novel Mutation in the PRNP Gene. <i>Archives of Neurology</i> , 2006, 63, 1016.                                      | 4.9 | 20        |
| 606 | The G2019S <i>LRRK2</i> mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.       | 2.2 | 20        |
| 607 | Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS4PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.         | 2.2 | 20        |
| 608 | Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.                               | 2.2 | 20        |
| 609 | Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011, 114, 1428-1431.                                | 0.9 | 20        |
| 610 | Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016, 25, 81-88.               | 1.5 | 20        |
| 611 | Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021, 36, 1342-1352.                   | 2.2 | 20        |
| 612 | Dopamine agonists and antagonists in the treatment of idiopathic dystonia. <i>Advances in Neurology</i> , 1988, 50, 561-70.   | 0.8 | 20        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 613 | Flunarizine in Essential Tremor. <i>Clinical Neuropharmacology</i> , 1993, 16, 460-463.  | 0.2 | 19        |
| 614 | Gestes antagonistes in the suppression of tics: "Tricks for tics". <i>Movement Disorders</i> , 1995, 10, 226-228.  | 2.2 | 19        |
| 615 | Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 331-335.  | 1.0 | 19        |
| 616 | Wilson Disease: Canadian Perspectives on Presentation And Outcomes from an Adult Ambulatory Setting. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 333-339.   | 1.8 | 19        |
| 617 | Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.   | 1.4 | 19        |
| 618 | Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017, 32, 1465-1473.  | 2.2 | 19        |
| 619 | Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.  | 1.1 | 19        |
| 620 | Clinical phenomenology of tic disorders selected aspects. <i>Advances in Neurology</i> , 1992, 58, 25-32.  | 0.8 | 19        |
| 621 | Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994, 9, 358-366.   | 2.2 | 18        |
| 622 | Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 523-527. | 0.9 | 18        |
| 623 | Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2002, 147, 322-331.   | 0.7 | 18        |
| 624 | Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.  | 2.2 | 18        |
| 625 | Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.  | 2.2 | 18        |
| 626 | Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.  | 1.5 | 18        |
| 627 | Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.  | 1.0 | 18        |
| 628 | Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.  | 2.2 | 18        |
| 629 | Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.   |     | 18        |
| 630 | Clinical diagnostic criteria. <i>Advances in Neurology</i> , 2000, 82, 29-34.  | 0.8 | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 631 | Coexistence of Idiopathic Parkinson's Disease and Creutzfeldt-Jakob Disease. Canadian Journal of Neurological Sciences, 1985, 12, 272-273.  | 0.3 | 17        |
| 632 | Association between familial tremor and Parkinson's disease. Annals of Neurology, 1986, 19, 306-306.  | 2.8 | 17        |
| 633 | Pallidotomy Increases Cortical Inhibition in Parkinson's Disease. Canadian Journal of Neurological Sciences, 1997, 24, 133-136.   | 0.3 | 17        |
| 634 | Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. Movement Disorders, 2003, 18, 942-948.  | 2.2 | 17        |
| 635 | Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment. Movement Disorders, 2004, 9, 173-177.   | 2.2 | 17        |
| 636 | Orthostatic tremor in progressive supranuclear palsy. Movement Disorders, 2007, 22, 1192-1194.  | 2.2 | 17        |
| 637 | Initiating dopaminergic treatment in Parkinson's disease. Lancet, The, 2014, 384, 1164-1166.  | 6.3 | 17        |
| 638 | Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. Parkinsonism and Related Disorders, 2014, 20, 915-918.   | 1.1 | 17        |
| 639 | Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11 C]raclopride positron emission tomography imaging study. Human Brain Mapping, 2015, 36, 2592-2601. | 1.9 | 17        |
| 640 | Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. Journal of Visualized Experiments, 2018, , .  | 0.2 | 17        |
| 641 | <p>Orthostatic hypotension and dementia incidence: links and implications</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2181-2194.  | 1.0 | 17        |
| 642 | Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. Movement Disorders, 2021, 36, 1483-1484.   | 2.2 | 17        |
| 643 | Anticholinergic Drugs and Amantadine in the Treatment of Parkinson's Disease. Handbook of Experimental Pharmacology, 1989, , 307-323.   | 0.9 | 17        |
| 644 | Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. PLoS ONE, 2017, 12, e0173944.  | 1.1 | 17        |
| 645 | Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. Human Brain Mapping, 2022, 43, 2089-2108.   | 1.9 | 17        |
| 646 | Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. Movement Disorders, 1996, 11, 448-449.  | 2.2 | 16        |
| 647 | Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: Is magnocellular function essential to reading motion-defined letters?. Vision Research, 1997, 37, 3531-3534.                                 | 0.7 | 16        |
| 648 | Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis. Clinical Neuropharmacology, 2001, 24, 242-244.   | 0.2 | 16        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 649 | Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. <i>Annals of Neurology</i> , 2002, 52, 257-258.   | 2.8 | 16        |
| 650 | Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 985-993.                                     | 1.4 | 16        |
| 651 | A case of a psychogenic "jumpy stump". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1101-1101.  | 0.9 | 16        |
| 652 | Diagnosing psychogenic movement disorders— which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 134-135.                                 | 2.7 | 16        |
| 653 | VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY. <i>Neurology</i> , 2007, 68, 1440-1441.  | 1.5 | 16        |
| 654 | Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. <i>Movement Disorders</i> , 2007, 22, 1708-1714. | 2.2 | 16        |
| 655 | The psychogenic toe signs. <i>Neurology</i> , 2011, 77, 508-509.  | 1.5 | 16        |
| 656 | Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. <i>Movement Disorders</i> , 2014, 29, 1707-1709.                        | 2.2 | 16        |
| 657 | Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.   | 1.5 | 16        |
| 658 | Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 141-142.   | 1.1 | 16        |
| 659 | Pharmacology of cranial dystonia. <i>Neurology</i> , 1983, 33, 1100-1100.   | 1.5 | 16        |
| 660 | Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. <i>Cmaj</i> , 1988, 139, 837-44.                                 | 0.9 | 16        |
| 661 | Lithium and parkinsonism. <i>Annals of Neurology</i> , 1984, 15, 214-214.   | 2.8 | 15        |
| 662 | A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families*. <i>American Journal of Human Genetics</i> , 2000, 67, 1314-1319.   | 2.6 | 15        |
| 663 | A new sensitive imaging biomarker for Parkinson disease?. <i>Neurology</i> , 2009, 72, 1374-1375.   | 1.5 | 15        |
| 664 | Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011, 26, 2296-2297.                                    | 2.2 | 15        |
| 665 | The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012, 27, 1308-1311.  | 2.2 | 15        |
| 666 | Designing Clinical Trials for Dystonia. <i>Neurotherapeutics</i> , 2014, 11, 117-127.   | 2.1 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 667 | The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.  | 1.8 | 15        |
| 668 | Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.   | 0.8 | 15        |
| 669 | Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.   | 1.1 | 15        |
| 670 | Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease. <i>Advances in Neurology</i> , 1997, 74, 167-74.  | 0.8 | 15        |
| 671 | Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.  | 0.4 | 15        |
| 672 | Subthalamic DBS replaces levodopa in Parkinson's disease. <i>Neurology</i> , 2002, 59, 1293-1294.  | 1.5 | 14        |
| 673 | Drug-induced cranial myoclonus. <i>Movement Disorders</i> , 2010, 25, 2264-2265.   | 2.2 | 14        |
| 674 | A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012, 27, 794-794.   | 2.2 | 14        |
| 675 | Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , 2013, 28, 274-281.  | 2.2 | 14        |
| 676 | Extensive intracranial calcifications in a patient with a novel polymerase gamma-1 mutation. <i>Neurology</i> , 2013, 81, 197-198.   | 1.5 | 14        |
| 677 | A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. <i>Movement Disorders</i> , 2014, 29, 743-749.  | 2.2 | 14        |
| 678 | Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 71. | 3.0 | 14        |
| 679 | Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.  | 0.8 | 14        |
| 680 | Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015, 15, 236.   | 0.8 | 14        |
| 681 | Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.   | 2.1 | 14        |
| 682 | The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.   | 1.4 | 14        |
| 683 | Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.  | 1.5 | 14        |
| 684 | Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.  | 1.7 | 14        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 685 | Positron tomography in dystonia. <i>Advances in Neurology</i> , 1988, 50, 249-53.  | 0.8  | 14        |
| 686 | Surgical treatment of dystonia. <i>Advances in Neurology</i> , 1998, 78, 185-98.   | 0.8  | 14        |
| 687 | GDNF in Parkinson's disease: The perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007, 163, 193-196.  | 1.3  | 13        |
| 688 | Functional/psychogenic movement disorders: Do we know what they are?. <i>Movement Disorders</i> , 2014, 29, 1696-1697.   | 2.2  | 13        |
| 689 | Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.  | 0.9  | 13        |
| 690 | Movement Disorders and Renal Diseases. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 763-779.   | 0.8  | 13        |
| 691 | Movement Disorders Due to Selective Basal Ganglia Lesions with Uremia. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 350-365.   | 0.3  | 13        |
| 692 | Clinical Differences Between Metoclopramide- and Antipsychotic-Induced Tardive Dyskinesias. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 137-139.  | 0.3  | 12        |
| 693 | Acute effect of transcutaneous electrical nerve stimulation on tremor. <i>Movement Disorders</i> , 2003, 18, 191-194.  | 2.2  | 12        |
| 694 | Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. <i>Movement Disorders</i> , 2003, 18, 1550-1554.                               | 2.2  | 12        |
| 695 | Subthalamic Stimulation for Parkinson's Disease "Living Better Electrically?". <i>New England Journal of Medicine</i> , 2003, 349, 1888-1891.  | 13.9 | 12        |
| 696 | Does severity of Parkinson's disease vary according to season?. <i>Movement Disorders</i> , 2005, 20, 476-479.   | 2.2  | 12        |
| 697 | Translational Research in Neurology and Neuroscience 2011. <i>Archives of Neurology</i> , 2011, 68, 709-16.  | 4.9  | 12        |
| 698 | Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.                         | 2.2  | 12        |
| 699 | Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.   | 2.2  | 12        |
| 700 | Remoxipride in the Treatment of Levodopa-Induced Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 395-399.   | 0.7  | 12        |
| 701 | Combining Skin $\alpha$ -Synuclein Real-time Quaking-induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 648-650. | 2.2  | 12        |
| 702 | $\alpha$ -Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. <i>Acta Neuropathologica</i> , 2022, 144, 167-185.  | 3.9  | 12        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 703 | Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. <i>Movement Disorders</i> , 1986, 1, 93-102.  | 2.2 | 11        |
| 704 | Update on Dopamine Agonists in Parkinson's Disease: "Beyond Bromocriptine". <i>Canadian Journal of Neurological Sciences</i> , 1987, 14, 474-482.  | 0.3 | 11        |
| 705 | Tizanidine in Cranial Dystonia. <i>Clinical Neuropharmacology</i> , 1992, 15, 142-147.   | 0.2 | 11        |
| 706 | Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. <i>Neurology</i> , 2002, 59, 1292-1292.   | 1.5 | 11        |
| 707 | Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.                               | 2.2 | 11        |
| 708 | Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007, 22, 1097-1101.  | 2.2 | 11        |
| 709 | Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007, 22, 2292-2293.  | 2.2 | 11        |
| 710 | Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 173-178.  | 0.3 | 11        |
| 711 | A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.   | 2.2 | 11        |
| 712 | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 151-156. | 2.5 | 11        |
| 713 | Dancing Dorsal Quadrilaterals. <i>JAMA Neurology</i> , 2019, 76, 351.  | 4.5 | 11        |
| 714 | The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.   | 1.1 | 11        |
| 715 | Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021, 36, 277-277.   | 2.2 | 11        |
| 716 | Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2419-2425.  | 2.2 | 11        |
| 717 | MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. <i>Sleep Medicine</i> , 2021, 83, 83-88.  | 0.8 | 11        |
| 718 | A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0178982.  | 1.1 | 11        |
| 719 | Small and Large Magnetic Resonance Imaging "Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.                                 | 2.2 | 11        |
| 720 | Cortical reflex myoclonus studied with cortical electrodes. <i>Clinical Neurophysiology</i> , 1999, 110, 1521-1530.  | 0.7 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 721 | Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004, 19, 1485-1492.   | 2.2 | 10        |
| 722 | Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011, 56, 671-675.                      | 1.1 | 10        |
| 723 | Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.   | 2.4 | 10        |
| 724 | Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.                                     | 0.8 | 10        |
| 725 | Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.                                  | 1.5 | 10        |
| 726 | Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.  | 1.4 | 10        |
| 727 | Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>Journal of the Neurological Sciences</i> , 2019, 396, 33-35.   | 0.3 | 10        |
| 728 | Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132. | 1.1 | 10        |
| 729 | Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.   | 0.7 | 10        |
| 730 | Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. <i>Advances in Neurology</i> , 1997, 74, 199-211.   | 0.8 | 10        |
| 731 | Spasmodic Dysphonia in Gilles de la Tourette's Disease. <i>Archives of Neurology</i> , 1983, 40, 51-52.  | 4.9 | 9         |
| 732 | Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004, 19, 580-583.  | 2.2 | 9         |
| 733 | Rasagiline-induced spontaneous ejaculation. <i>Movement Disorders</i> , 2009, 24, 2160-2161.   | 2.2 | 9         |
| 734 | Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010, 206, 1-13.   | 0.7 | 9         |
| 735 | The grasp reflex: A symptom in need of treatment. <i>Movement Disorders</i> , 2010, 25, 2479-2485.   | 2.2 | 9         |
| 736 | LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.   | 1.5 | 9         |
| 737 | Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012, 78, 838-838.   | 1.5 | 9         |
| 738 | Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.   | 2.8 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 739 | A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. <i>Brain</i> , 2016, 139, 2609-2616.   | 3.7 | 9         |
| 740 | Basal ganglia calcification in a case of PKAN. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 98-99.   | 1.1 | 9         |
| 741 | Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders". <i>Movement Disorders</i> , 2020, 35, 1903-1904.   | 2.2 | 9         |
| 742 | DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.   | 1.5 | 9         |
| 743 | Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease. <i>Experimental Brain Research</i> , 2021, 239, 1551-1565.   | 0.7 | 9         |
| 744 | Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.  | 0.8 | 9         |
| 745 | A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.  | 2.2 | 9         |
| 746 | Long latency between the onset of motor and vocal tics in Tourette's syndrome. <i>Annals of Neurology</i> , 1983, 14, 693-694.  | 2.8 | 8         |
| 747 | Stiff-Person Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1992, 19, 383-388.  | 0.3 | 8         |
| 748 | Farewell from the outgoing editors. <i>Movement Disorders</i> , 2004, 19, 2-2.  | 2.2 | 8         |
| 749 | Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.   | 0.6 | 8         |
| 750 | Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 961-962.  | 2.2 | 8         |
| 751 | Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.  | 2.2 | 8         |
| 752 | Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.  | 0.8 | 8         |
| 753 | Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.  | 1.1 | 8         |
| 754 | Successful spinal cord stimulation for severe medication-refractory restless legs syndrome. <i>Movement Disorders</i> , 2019, 34, 585-586.  | 2.2 | 8         |
| 755 | Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.  | 1.1 | 8         |
| 756 | The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198. | 1.1 | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 757 | Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.                                     | 1.5 | 8         |
| 758 | The Effects of Pallidotomy on Parkinson's Disease: Study Design and Assessment Techniques. <i>Acta Neurochirurgica Supplementum</i> , 1997, 68, 24-28.  | 0.5 | 8         |
| 759 | Parkinsonian Tremor. <i>Neurological Disease and Therapy</i> , 2005, , 195-220.   | 0.0 | 8         |
| 760 | Patterns of Mixed Pathologies in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 595-607.  | 1.2 | 8         |
| 761 | Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.   | 1.7 | 8         |
| 762 | Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.   |     | 7         |
| 763 | “Weight-holding tremor”: An unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995, 10, 228-229.   | 2.2 | 7         |
| 764 | Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 235-237.   | 2.2 | 7         |
| 765 | Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. <i>Movement Disorders</i> , 2003, 18, 1070-1072.                                    | 2.2 | 7         |
| 766 | FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.   | 1.5 | 7         |
| 767 | Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011, 26, 2297-2298.  | 2.2 | 7         |
| 768 | Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.                               | 1.1 | 7         |
| 769 | Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. <i>Neurological Sciences</i> , 2018, 39, 1797-1800.                                 | 0.9 | 7         |
| 770 | Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 491-498.   | 0.3 | 7         |
| 771 | The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.   | 1.1 | 7         |
| 772 | Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.   | 1.1 | 7         |
| 773 | PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574. | 1.1 | 7         |
| 774 | Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020, 143, e36-e36.   | 3.7 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 775 | Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 997-1011.  | 0.8 | 7         |
| 776 | Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.                          | 1.8 | 7         |
| 777 | Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999, 80, 575-83.  | 0.8 | 7         |
| 778 | Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002, 89, 77-83.   | 0.8 | 7         |
| 779 | Focal paroxysmal kinesigenic choreoathetosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1984, 47, 1057-1058.   | 0.9 | 6         |
| 780 | Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. <i>Annals of Neurology</i> , 1990, 28, 592-593.   | 2.8 | 6         |
| 781 | Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 157-184.   | 1.0 | 6         |
| 782 | Alien hand syndrome and dystonia in a pediatric patient. <i>Movement Disorders</i> , 2009, 24, 1557-1559.  | 2.2 | 6         |
| 783 | A Survey on the Impact of the Menstrual Cycle on Movement Disorders Severity. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 478-481.  | 0.3 | 6         |
| 784 | Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. <i>International Journal of Neuroscience</i> , 2011, 121, 472-476. | 0.8 | 6         |
| 785 | Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 76-78.  | 0.8 | 6         |
| 786 | Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 295-298.   | 0.8 | 6         |
| 787 | Deep Brain Stimulation for Parkinson Disease in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 367.  | 4.5 | 6         |
| 788 | Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo <i>ATP1A3</i> c.2267G>A (p.R756H) Genetic Mutation. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 74-75.                           | 0.8 | 6         |
| 789 | Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.   | 4.9 | 6         |
| 790 | Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018, 190, E50-E52.  | 0.9 | 6         |
| 791 | Neurostimulation for Functional Neurological Disorder: Evaluating Longitudinal Neurophysiology. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 561-563.  | 0.8 | 6         |
| 792 | Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 255-257.  | 1.1 | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 793 | The Waiting Room: neurological observations made outside the movement disorder specialist's consulting office. <i>Practical Neurology</i> , 2019, 19, 295-301.  | 0.5 | 6         |
| 794 | Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 228-230.  | 1.1 | 6         |
| 795 | Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 231-233. | 1.1 | 6         |
| 796 | Twinkle-associated familial parkinsonism with Lewy pathology. <i>Neurology</i> , 2020, 95, 644-647.   | 1.5 | 6         |
| 797 | Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.         | 1.1 | 6         |
| 798 | Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.  |     | 6         |
| 799 | Corticobasal ganglionic degeneration and/or frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 705-705.   | 0.9 | 6         |
| 800 | Parkinson's disease in 1984: an update. <i>Cmaj</i> , 1984, 131, 1031-7.  | 0.1 | 6         |
| 801 | Update on the treatment of tics. <i>Advances in Neurology</i> , 2001, 85, 355-62.   | 0.8 | 6         |
| 802 | Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 522-529.  | 0.8 | 6         |
| 803 | Insulin-induced hypoglycaemia does not abolish chorea.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 936-937.   | 0.9 | 5         |
| 804 | Treatment of Early Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, S39-S44.   | 0.3 | 5         |
| 805 | Reporting clinical trials. <i>Neurology</i> , 2002, 58, 347-348.  | 1.5 | 5         |
| 806 | Reporting clinical trials: Full access to all the data. <i>Movement Disorders</i> , 2002, 17, 3-4.  | 2.2 | 5         |
| 807 | Title is missing!. <i>Current Opinion in Neurology</i> , 2003, 16, 523-527.   | 1.8 | 5         |
| 808 | Reply: Parkinson's disease, DBS and suicide: a role for serotonin?. <i>Brain</i> , 2009, 132, e127-e127.  | 3.7 | 5         |
| 809 | Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 772-774.   | 0.8 | 5         |
| 810 | Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.  | 3.7 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 811 | Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 20, 222-227.   | 1.4 | 5         |
| 812 | [ <sup>18</sup> F]AV $\beta$ 1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018, 33, 1360-1361.   | 2.2 | 5         |
| 813 | Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. <i>Pediatric Neurology</i> , 2020, 103, 76-78.  | 1.0 | 5         |
| 814 | A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021, 36, 999-1005.   | 2.2 | 5         |
| 815 | Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.           | 1.5 | 5         |
| 816 | Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. <i>Movement Disorders</i> , 2022, , .                               | 2.2 | 5         |
| 817 | <i>DYT4</i> ( <i>DYT4</i> Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.              | 0.8 | 5         |
| 818 | Sudden confusion with levodopa withdrawal. <i>Movement Disorders</i> , 1987, 2, 223-223.  | 2.2 | 4         |
| 819 | What is it? Case 1, 1987: Unusual tremors, bradykinesia, and cerebral lucencies. <i>Movement Disorders</i> , 1987, 2, 321-338.  | 2.2 | 4         |
| 820 | Case 1, 1991: A severe and fatal systemic illness first presenting with a movement disorder. <i>Movement Disorders</i> , 1991, 6, 362-370.                                | 2.2 | 4         |
| 821 | Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.  | 2.2 | 4         |
| 822 | Reporting clinical trials: full access to all the data. <i>European Journal of Neurology</i> , 2002, 9, 123-124.  | 1.7 | 4         |
| 823 | Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004, 19, 534-543.  | 2.2 | 4         |
| 824 | Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.         | 0.3 | 4         |
| 825 | Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 283-283.  | 2.8 | 4         |
| 826 | Acute akathisia. , 0, , 3-19.   |     | 4         |
| 827 | Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.                     | 0.6 | 4         |
| 828 | Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report. <i>Neurocase</i> , 2016, 22, 215-219. | 0.2 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 829 | A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018, 33, 850-852.  | 2.2 | 4         |
| 830 | Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.   | 0.8 | 4         |
| 831 | Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.   | 0.8 | 4         |
| 832 | Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.                      | 1.5 | 4         |
| 833 | <scp>Age-Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.   | 2.2 | 4         |
| 834 | Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.  | 2.2 | 4         |
| 835 | Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.  | 2.2 | 4         |
| 836 | Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.  | 0.8 | 4         |
| 837 | The second family affected with a PRDM8-related disease. <i>Neurological Sciences</i> , 2022, 43, 3847-3855.   | 0.9 | 4         |
| 838 | Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598. | 2.1 | 4         |
| 839 | The Interaction between <scp><i>HLA-DRB1</i></scp> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.  | 2.2 | 4         |
| 840 | Potential benefits of dopamine striatal implant. <i>Annals of Neurology</i> , 1990, 27, 109-110.   | 2.8 | 3         |
| 841 | CQA 206-291 in Parkinson's Disease: An Acute Single Escalating Dosage Study. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 416-419.   | 0.3 | 3         |
| 842 | Effect of GPi pallidotomy on neuropsychological function in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 1997, 12, 419-419.  | 0.3 | 3         |
| 843 | Neonatal Ablation of the Nigrostriatal Dopamine Pathway Does Not Influence Limb Development in Rats. <i>Experimental Neurology</i> , 2002, 177, 547-556.                                       | 2.0 | 3         |
| 844 | Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.   | 2.2 | 3         |
| 845 | Deep brain stimulation for dystonia. <i>Movement Disorders</i> , 2011, 26, S3-4.   | 2.2 | 3         |
| 846 | Hemiballismâ€“Hemichorea. , 2013, , 151-161.   |     | 3         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 847 | Efficacy and safety of T2000 in older patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 485-486.  | 1.1 | 3         |
| 848 | Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. <i>Neurology</i> , 2015, 85, 742-743.  | 1.5 | 3         |
| 849 | Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 447-448.                             | 0.3 | 3         |
| 850 | Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 39-41.                                      | 0.8 | 3         |
| 851 | Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.   | 1.5 | 3         |
| 852 | Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 433-435.         | 0.8 | 3         |
| 853 | Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.                     | 2.2 | 3         |
| 854 | Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 224-227.                        | 1.1 | 3         |
| 855 | Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 360-362.   | 0.7 | 3         |
| 856 | Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 120-121.                      | 0.8 | 3         |
| 857 | Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1047-1055.  | 1.5 | 3         |
| 858 | Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 171-177.                                      | 2.2 | 3         |
| 859 | Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.                              | 0.8 | 3         |
| 860 | Multimodal Longitudinal Neurophysiological Investigations in Dopa-Responsive Dystonia. <i>Movement Disorders</i> , 2021, 36, 1986-1987.   | 2.2 | 3         |
| 861 | A Novel COVID Era-Related Oromandibular Dyskinesia: Surgical Mask-Induced Dyskinesia?. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 470-471.                                      | 0.3 | 3         |
| 862 | Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 40-46.  | 1.1 | 3         |
| 863 | Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465. | 1.3 | 3         |
| 864 | Targeted copy number variant identification across the neurodegenerative disease spectrum. <i>Molecular Genetics &amp; Genomic Medicine</i> , 0, , .  | 0.6 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 865 | Iris pigmentation in idiopathic dystonia. <i>Annals of Neurology</i> , 1982, 12, 585-586.   | 2.8 | 2         |
| 866 | Hemiballism-Hemichorea. <i>Archives of Neurology</i> , 1990, 47, 619-619.   | 4.9 | 2         |
| 867 | Corticobasal degeneration syndrome with basal ganglia calcification: Fahr's disease as a corticobasal look-alike?. <i>Movement Disorders</i> , 2003, 18, 351-352.                         | 2.2 | 2         |
| 868 | Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.  |     | 2         |
| 869 | Multiple system atrophy. , 2005, , 623-662.   |     | 2         |
| 870 | Clinical Practice Regarding Dopamine-Agonist Use and Driving in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 438-442.                                | 0.3 | 2         |
| 871 | Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies. <i>Archives of Neurology</i> , 2009, 66, 1285-7.     | 4.9 | 2         |
| 872 | Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012, 2, 167-170.  | 0.3 | 2         |
| 873 | Extreme task specificity: Is it dystonia or another form of motor programming abnormality?. <i>Movement Disorders</i> , 2012, 27, 1202-1203.  | 2.2 | 2         |
| 874 | In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.  | 4.9 | 2         |
| 875 | On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1290-1291.  | 1.1 | 2         |
| 876 | Levodopa and Parkinson Disease—Myths Revisited—Reply. <i>JAMA Neurology</i> , 2017, 74, 1270.   | 4.5 | 2         |
| 877 | Is there even such a thing as "idiopathic normal pressure hydrocephalus"? <i>Annals of Neurology</i> , 2017, 82, 1032-1032.   | 2.8 | 2         |
| 878 | Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 782-784.                                | 0.3 | 2         |
| 879 | Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 349-351.   | 1.1 | 2         |
| 880 | Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 403-405. | 0.8 | 2         |
| 881 | Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 133-134.                | 1.1 | 2         |
| 882 | Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.  | 4.9 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 883 | Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020, 94, 144-145.  | 1.5 | 2         |
| 884 | Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80. | 1.1 | 2         |
| 885 | Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.   | 3.7 | 2         |
| 886 | Reply to: "The Logic and Pitfalls of Parkinson's as Brain Versus Body First Subtypes" <i>Movement Disorders</i> , 2021, 36, 786-787.   | 2.2 | 2         |
| 887 | Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Lusian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 594-599.   | 0.8 | 2         |
| 888 | Neuropsychiatric disorders and COVID-19. <i>Lancet Psychiatry</i> , 2021, 8, 564-565.  | 3.7 | 2         |
| 889 | Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.                       | 1.4 | 2         |
| 890 | Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 297-310.  | 0.8 | 2         |
| 891 | Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 311-325.   | 0.8 | 2         |
| 892 | Parkinsonism in corticobasal degeneration. <i>Advances in Neurology</i> , 2000, 82, 83-9.  | 0.8 | 2         |
| 893 | Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring" <i>Movement Disorders Clinical Practice</i> , 2022, 9, 501-507.  | 0.8 | 2         |
| 894 | Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease. <i>Brain</i> , 0, , .  | 3.7 | 2         |
| 895 | Letters to the editor. <i>Movement Disorders</i> , 1996, 11, 342-345.  | 2.2 | 1         |
| 896 | 69-Year-old man with gait disturbance and parkinsonism. <i>Movement Disorders</i> , 2001, 16, 548-561.   | 2.2 | 1         |
| 897 | <i>Movement Disorders: an Overview.</i> , 0, , 3-19.   |     | 1         |
| 898 | Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.   |     | 1         |
| 899 | Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 252-272.  | 0.1 | 1         |
| 900 | Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.  |     | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 901 | Crossing the borders between neurology and psychiatry in functional neurological disorders. <i>Movement Disorders</i> , 2011, 26, 1373-1374.  | 2.2 | 1         |
| 902 | Commentary. <i>Movement Disorders</i> , 2013, 28, 1806-1807.  | 2.2 | 1         |
| 903 | Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2013, 81, 1181-1181.  | 1.5 | 1         |
| 904 | Reply to: Gray et al. <i>Movement Disorders</i> , 2014, 29, 1225-1226.  | 2.2 | 1         |
| 905 | Reply: Dystonia after severe head injuries. <i>Movement Disorders</i> , 2014, 29, 578-579.  | 2.2 | 1         |
| 906 | Focal Predominant Forms of Posthypoxic Action Myoclonus. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 417-420.  | 0.8 | 1         |
| 907 | Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive/Compulsive Behaviors. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 412-414.  | 0.8 | 1         |
| 908 | Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 53-58.  | 0.8 | 1         |
| 909 | Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016, 31, 1760-1762.         | 2.2 | 1         |
| 910 | CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 212-214.  | 0.8 | 1         |
| 911 | Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation. <i>Clinical Neurophysiology</i> , 2019, 130, 1750-1751.  | 0.7 | 1         |
| 912 | Gelastic Cataplexy in Niemann Pick Type C. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 498-499.  | 0.8 | 1         |
| 913 | Isolated lingual myoclonus in an HIV patient. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 241-244.  | 1.1 | 1         |
| 914 | Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 780-782. | 2.0 | 1         |
| 915 | Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 103-108.  | 0.6 | 1         |
| 916 | Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.   | 0.3 | 1         |
| 917 | Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1125-1125.  | 2.2 | 1         |
| 918 | Teaching Video Neurolmage: "Weighing" in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971.  | 1.5 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 919 | Exacerbation of Stiff Person Syndrome by Selective Serotonin Reuptake Inhibitors. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 772-774.   | 0.8 | 1         |
| 920 | Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 791-793.  | 0.8 | 1         |
| 921 | Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04712.   | 0.2 | 1         |
| 922 | The Discovery of $\alpha$ -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1189-1193.         | 0.8 | 1         |
| 923 | Commentary: Is Tardive Dyskinesia Disappearing?. , 0, , 302-310.  |     | 1         |
| 924 | Rating Scales for Movement Disorders. , 0, , 20-29.   |     | 1         |
| 925 | Identical twins with progressive kyphoscoliosis and ophthalmoplegia. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 119-122.   | 1.1 | 1         |
| 926 | Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia. <i>Movement Disorders Clinical Practice</i> , 0, , .   | 0.8 | 1         |
| 927 | The Role of Insular Cortex in Gut Inflammation Memory: What Does It Mean for Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 700-701.   | 2.2 | 1         |
| 928 | Genomic study of a large family with complex neurological phenotype including hearing loss, imbalance and action tremor. <i>Neurobiology of Aging</i> , 2022, 113, 137-142.               | 1.5 | 1         |
| 929 | Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 15-17.                                       | 1.1 | 1         |
| 930 | Recommendations for Virtual Administration of the <scp>PSP</scp> Rating Scale. <i>Movement Disorders</i> , 2022, 37, 1960-1961.   | 2.2 | 1         |
| 931 | What is it? Case 1, 1992: Progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. <i>Movement Disorders</i> , 1992, 7, 373-379. | 2.2 | 0         |
| 932 | Reporting clinical trials: full access to all the data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 143-143.   | 0.9 | 0         |
| 933 | Reporting clinical trials: Full access to all the data. <i>Muscle and Nerve</i> , 2002, 25, 133-134.  | 1.0 | 0         |
| 934 | Normalization of voice in spasmodic dysphonia during transient global amnesia. <i>Movement Disorders</i> , 2005, 20, 1228-1229.   | 2.2 | 0         |
| 935 | Corticobasal degeneration. , 2005, , 682-696.   |     | 0         |
| 936 | Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.  |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 937 | Current and potential treatments of Parkinson's disease. , 2005, , 612-622.  |     | 0         |
| 938 | Can visual hallucinations be used as a diagnostic factor in Parkinson's disease?. Nature Clinical Practice Neurology, 2006, 2, 246-247.                        | 2.7 | 0         |
| 939 | An update on movement disorders: exciting developments but new obstacles. Current Opinion in Neurology, 2007, 20, 432-433.                                     | 1.8 | 0         |
| 940 | Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. Movement Disorders, 2008, 23, 925-925.                       | 2.2 | 0         |
| 941 | Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.   |     | 0         |
| 942 | PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 182-193.   | 0.4 | 0         |
| 943 | Dopamine Agonists vs Levodopa in Impulse Control Disordersâ€”Reply. Archives of Neurology, 2011, 68, 544.  | 4.9 | 0         |
| 944 | Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. Movement Disorders, 2013, 28, 405-406.                                | 2.2 | 0         |
| 945 | Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408. | 2.2 | 0         |
| 946 | The Saskatchewan Movement Disorders Program: Commitment Pays Off. Canadian Journal of Neurological Sciences, 2015, 42, 70-71.                                  | 0.3 | 0         |
| 947 | Restless Genital Syndromeâ€”Reply. JAMA Neurology, 2015, 72, 479.  | 4.5 | 0         |
| 948 | Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.  |     | 0         |
| 949 | The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.  |     | 0         |
| 950 | Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. JAMA Neurology, 2019, 76, 985.   | 4.5 | 0         |
| 951 | Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€• Parkinsonism and Related Disorders, 2019, 66, 245-246.                     | 1.1 | 0         |
| 952 | Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. European Journal of Neurology, 2019, 26, e66-e67.      | 1.7 | 0         |
| 953 | Preface to the Video Challenge Supplement for Movement Disorders Clinical Practice. Movement Disorders Clinical Practice, 2020, 7, S53-S54.                    | 0.8 | 0         |
| 954 | â€œOpeningâ€•New Insights Into <i>LRRK2</i> Conformation and the Microtubule. Movement Disorders, 2020, 35, 2162-2163.   | 2.2 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 955 | Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative. <i>Alzheimer's and Dementia</i> , 2020, 16, e044540. | 0.4 | 0         |
| 956 | Phenotype differences between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046071.  | 0.4 | 0         |
| 957 | Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .   |     | 0         |
| 958 | Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266.   | 2.2 | 0         |
| 959 | Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343.  | 0.9 | 0         |
| 960 | Sleepiness and Sleep Attacks in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 385-390.   | 0.2 | 0         |
| 961 | Acute Effects of Levodopa and Pallidotomy on Bimanual Repetitive Arm Movements in Patients with Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 43-50.   | 0.2 | 0         |
| 962 | Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.  | 0.2 | 0         |
| 963 | Surgery for Movement Disorders: An Overview. , 2009, , 1443-1466.   |     | 0         |
| 964 | Other Movement Disorders. , 2012, , 2333-2342.  |     | 0         |
| 965 | Psychogenic dystonia. , 2012, , 307-319.  |     | 0         |
| 966 | Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 55.  | 1.1 | 0         |
| 967 | Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>Neurotherapeutics</i> , 2006, 3, 192-206.  | 2.1 | 0         |
| 968 | Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-1 GCH1. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 734-736.   | 0.3 | 0         |
| 969 | Teaching Video NeuroImage: Unilateral Myorhythmia in a Patient With a Midbrain-Diencephalic Junction Cavernous Malformation. <i>Neurology</i> , 2022, 98, .   | 1.5 | 0         |
| 970 | Teaching Video NeuroImage: Reversible Caudate Changes in a Patient With Post-Pump Chorea. <i>Neurology</i> , 2022, 98, 731-732.   | 1.5 | 0         |
| 971 | Differential cognitive correlates of tau and neurofilament light chain in cerebrospinal fluid of frontotemporal lobar degeneration patients with and without Alzheimer's markers. <i>Alzheimer's and Dementia</i> , 2021, 17, .                           | 0.4 | 0         |
| 972 | Evolution of Parkinson's Disease and Treatment Requirements: What New Treatments are Needed and the Role of Striatal Grafting. , 2006, , 50-64.   |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 973 | Patient Selection for Movement Disorders Surgery. , 0, , 53-68.   |     | 0         |
| 974 | Posteroventral medial pallidotomy in Parkinson's disease. Journal of Neurology, 1999, 246, s028-s041.   | 1.8 | 0         |
| 975 | Periodic Limb Movements While Awake (PLMA) as a manifestation of Wearingâ€™Off in Parkinson's Disease: A Case Series and Review of the Literature. Movement Disorders Clinical Practice, 0, , . | 0.8 | 0         |
| 976 | Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease. JAMA Neurology, 2022, 79, 726.  | 4.5 | 0         |